Conservatives Press Trump on Mifepristone Review Amid Midterm Concerns

Anti-abortion advocates are increasingly urging President Donald Trump to expedite the review of mifepristone, an abortion pill that has been approved since 2000. The review, conducted by the Food and Drug Administration (FDA), could potentially alter the drug's approval status and restrict its availability. Despite Trump's previous commitment to leave abortion policy to the states, conservative lawmakers are pressing for more decisive action, fearing that a lack of progress could jeopardize the Republican Party's standing in the upcoming midterm elections.

The HillThe Hill

The urgency among anti-abortion groups stems from concerns that the continued availability of mifepristone, particularly through telemedicine, undermines their goals following the Supreme Court's decision to overturn Roe v. Wade. The conservative nonprofit Susan B. Anthony (SBA) Pro-Life America has been vocal in its dissatisfaction, calling for the dismissal of FDA Commissioner Marty Makary due to perceived delays in the review process. Senator Bill Cassidy (R-La.), chair of the Senate Committee on Health, Education, Labor and Pensions, echoed these sentiments, emphasizing the need for transparency regarding the safety study of mifepristone.

The Hill

While some conservative lawmakers are advocating for stricter abortion policies, others within the GOP, particularly those in swing states, may prefer to avoid the issue altogether. This division highlights the complex dynamics at play as Republicans navigate the political landscape leading up to the midterms. Liz Mair, a GOP consultant, noted that Trump's current position allows him to prioritize broader party interests over specific anti-abortion demands, especially given his declining approval ratings.

The Hill

In response to the calls for action, a spokesperson for the White House defended Makary, stating that he is committed to conducting a thorough review based on "Gold Standard Science." However, the growing dissatisfaction among anti-abortion factions suggests that the administration's approach may not align with their expectations. Former Vice President Mike Pence's organization, Advancing American Freedom, has also called for Health and Human Services Secretary Robert F. Kennedy Jr. to be removed from his position, citing a lack of action on mifepristone.

The Hill

Critics argue that the Trump administration's hesitance to take a firmer stance on mifepristone reflects broader political calculations rather than a commitment to anti-abortion principles. Some GOP members express concern that prioritizing stringent abortion policies could alienate moderate voters, as evidenced by the outcomes of the 2022 midterms, where voters favored abortion access in various ballot measures.

The Hill

As the midterm elections approach, the pressure on Trump and his administration to address the mifepristone review intensifies. The outcome of this review could significantly impact the GOP's strategy and voter sentiment, particularly among conservative constituents who are eager for more decisive action on abortion-related issues.

The Hill